Save Product
Product Details
Synonyms
IL33, DV27, C9ORF26, IL1F11, NFHEV, DKFZp586H0523, DVS27, NFEHEV, RP11-575C20.2
Source
Human IL-33 (2-270) Protein, His Tag (IL3-H51H3) is expressed from E. coli cells. It contains AA Lys 2 - Thr 270 (Accession # O95760-1).
Predicted N-terminus: Met
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 32.6 kDa. The protein migrates as 8 kDa,29 kDa and 33-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human IL-33 (2-270) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Human IL-1RL1, Fc Tag (Cat. No. IL1-H5250) at 5 μg/mL (100 μL/well) can bind Human IL-33 (2-270) Protein, His Tag (Cat. No. IL3-H51H3) with a linear range of 0.01-0.625 μg/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Interleukin-33
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
9 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
